JP2024099770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024099770A5 JP2024099770A5 JP2024073380A JP2024073380A JP2024099770A5 JP 2024099770 A5 JP2024099770 A5 JP 2024099770A5 JP 2024073380 A JP2024073380 A JP 2024073380A JP 2024073380 A JP2024073380 A JP 2024073380A JP 2024099770 A5 JP2024099770 A5 JP 2024099770A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- nucleic acid
- acid trans
- splicing molecule
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims 7
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 108090000565 Capsid Proteins Proteins 0.000 claims 4
- 102100023321 Ceruloplasmin Human genes 0.000 claims 4
- 108700024394 Exon Proteins 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 101150039555 ABCA4 gene Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000000608 photoreceptor cell Anatomy 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000001566 pro-viral effect Effects 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026037564A JP2026095408A (ja) | 2018-04-17 | 2026-03-10 | トランススプライシング分子 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658658P | 2018-04-17 | 2018-04-17 | |
| US201862658667P | 2018-04-17 | 2018-04-17 | |
| US62/658,658 | 2018-04-17 | ||
| US62/658,667 | 2018-04-17 | ||
| PCT/US2019/027981 WO2019204514A1 (en) | 2018-04-17 | 2019-04-17 | Trans-splicing molecules |
| JP2020557945A JP7561624B2 (ja) | 2018-04-17 | 2019-04-17 | トランススプライシング分子 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557945A Division JP7561624B2 (ja) | 2018-04-17 | 2019-04-17 | トランススプライシング分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037564A Division JP2026095408A (ja) | 2018-04-17 | 2026-03-10 | トランススプライシング分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099770A JP2024099770A (ja) | 2024-07-25 |
| JP2024099770A5 true JP2024099770A5 (enExample) | 2025-01-21 |
Family
ID=68239871
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557945A Active JP7561624B2 (ja) | 2018-04-17 | 2019-04-17 | トランススプライシング分子 |
| JP2024073380A Pending JP2024099770A (ja) | 2018-04-17 | 2024-04-30 | トランススプライシング分子 |
| JP2026037564A Pending JP2026095408A (ja) | 2018-04-17 | 2026-03-10 | トランススプライシング分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557945A Active JP7561624B2 (ja) | 2018-04-17 | 2019-04-17 | トランススプライシング分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026037564A Pending JP2026095408A (ja) | 2018-04-17 | 2026-03-10 | トランススプライシング分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11993776B2 (enExample) |
| EP (1) | EP3781213A4 (enExample) |
| JP (3) | JP7561624B2 (enExample) |
| KR (2) | KR20250150157A (enExample) |
| CN (1) | CN112449605B (enExample) |
| AU (2) | AU2019255708B2 (enExample) |
| BR (1) | BR112020021228A2 (enExample) |
| CA (1) | CA3097004A1 (enExample) |
| IL (2) | IL327341A (enExample) |
| MX (2) | MX2020010959A (enExample) |
| WO (1) | WO2019204514A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250150157A (ko) | 2018-04-17 | 2025-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| BR112021020539A2 (pt) * | 2019-04-17 | 2022-01-04 | Univ Pennsylvania | Terminador de hélice tripla para trans-splicing de rna eficiente |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| JP2024533163A (ja) | 2021-09-03 | 2024-09-12 | タシト・セラピューティクス・インコーポレーテッド | スプライソソーム構成要素のリクルートを介したｒｎａ編集 |
| KR20250011939A (ko) * | 2022-05-13 | 2025-01-22 | 아시디엔 테라퓨틱스, 인크. | Abca4 트랜스-스플라이싱 분자 |
| EP4551703A2 (en) * | 2022-07-07 | 2025-05-14 | Aldevron, LLC | Ocular vectors and uses thereof |
| US20260109985A1 (en) * | 2022-09-30 | 2026-04-23 | Centre National De La Recherche Scientifique | Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations |
| CN120569476A (zh) | 2022-11-30 | 2025-08-29 | 安铂生物公司 | 用于靶向反式剪接的方法和组合物 |
| IL322776A (en) * | 2023-02-15 | 2025-10-01 | Ascidian Therapeutics Inc | Htt trans-splicing molecules |
| WO2025166360A1 (en) * | 2024-02-03 | 2025-08-07 | Duke University | Compositions for and methods of engineering the transcriptome |
| US12655424B2 (en) | 2024-02-05 | 2026-06-16 | Amber Bio Inc. | Methods and compositions for trans-splicing utilizing small nuclear RNAs and small nucleolar RNAs |
| WO2026012439A1 (en) * | 2024-07-11 | 2026-01-15 | Sichuan Real & Best Biotech Co., Ltd. | Rna trans-splicing molecules and systems |
| US12686869B1 (en) | 2026-01-23 | 2026-07-21 | Amber Bio Inc. | Methods and compositions for trans-splicing utilizing trifunctional elements |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280978B1 (en) | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| EP0883344B2 (en) | 1995-12-15 | 2010-06-09 | VIRxSYS Corporation | Therapeutic molecules generated by trans-splicing |
| EP0938381B1 (en) | 1996-10-04 | 2012-12-26 | Veri-Q Inc. | Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation |
| US6929907B2 (en) | 1999-12-31 | 2005-08-16 | North Carolina State University | Methods and compositions for determining the purity of chemically synthesized nucleic acids |
| CA2452690C (en) | 2001-06-29 | 2016-08-16 | Veri-Q, Inc. | Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids |
| AU2003215249B2 (en) | 2002-02-12 | 2008-07-03 | Virxsys Corporation | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US7399753B2 (en) | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
| CA2477295A1 (en) | 2002-02-25 | 2003-09-04 | Intronn, Inc. | Trans-splicing mediated imaging of gene expression |
| WO2003104412A2 (en) | 2002-06-05 | 2003-12-18 | Intronn, Inc. | Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling |
| AU2003247505A1 (en) | 2002-06-05 | 2003-12-22 | University Of Iowa Research Foundation | Spliceosome mediated rna trans-splicing in stem cells |
| US20040018622A1 (en) | 2002-07-17 | 2004-01-29 | Mitchell Lloyd G. | Spliceosome mediated RNA trans-splicing for correction of skin disorders |
| AU2003285009B2 (en) | 2002-10-23 | 2010-10-07 | Virxsys Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| WO2005070023A2 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing |
| WO2005070948A1 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
| WO2006026611A2 (en) | 2004-08-31 | 2006-03-09 | Mitchell Lloyd G | Reverse transcriptase mediated rna gene expression |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US20090214478A1 (en) | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| AU2013234376B2 (en) * | 2008-10-22 | 2016-07-28 | Acucela, Inc. | Compounds for treating ophthalmic diseases and disorders |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| ES2646716T3 (es) | 2011-09-05 | 2017-12-15 | Stichting Katholieke Universiteit | Oligonucleótidos antisentido para el tratamiento de amaurosis congénita de Leber |
| CN105120901A (zh) | 2012-07-11 | 2015-12-02 | 宾夕法尼亚大学托管会 | Rpgr x染色体连锁视网膜退化的aav介导的基因治疗 |
| CN104955951A (zh) | 2012-10-16 | 2015-09-30 | 麻省理工学院 | 稳定的非多腺苷酸化rna的产生 |
| GB201219762D0 (en) | 2012-11-02 | 2012-12-19 | Bauer Johann | A RNA trans-splicing molecule (RTM) for use in the treatment of cancer |
| US10266845B2 (en) | 2013-02-08 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| DK2986635T3 (en) | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| US10155794B2 (en) | 2013-07-16 | 2018-12-18 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of disorders related to CEP290 |
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| LT3167076T (lt) | 2014-07-09 | 2022-02-10 | Lexogen Gmbh | Metodai ir produktai, skirti rnr transkripto variantų kiekybiniam įvertinimui |
| CA2979120A1 (en) | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof |
| AU2016355343C1 (en) | 2015-11-19 | 2024-10-03 | Lloyd G. Mitchell | Compositions and methods for correction of heritable ocular disease |
| JP7036723B2 (ja) * | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| CA3071769A1 (en) | 2017-07-31 | 2019-02-07 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
| US11795455B2 (en) | 2017-07-31 | 2023-10-24 | Massachusetts Institute Of Technology | RNA cleavage-induced transcript stabilizer and uses thereof |
| KR20250150157A (ko) | 2018-04-17 | 2025-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| BR112021020539A2 (pt) | 2019-04-17 | 2022-01-04 | Univ Pennsylvania | Terminador de hélice tripla para trans-splicing de rna eficiente |
| WO2020214990A1 (en) | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
| CN113795155A (zh) | 2019-05-01 | 2021-12-14 | 宝洁公司 | 产生短链脂肪酸的益生菌菌株和包含该益生菌菌株的组合物 |
| KR20250011939A (ko) | 2022-05-13 | 2025-01-22 | 아시디엔 테라퓨틱스, 인크. | Abca4 트랜스-스플라이싱 분자 |
-
2019
- 2019-04-17 KR KR1020257032132A patent/KR20250150157A/ko active Pending
- 2019-04-17 IL IL327341A patent/IL327341A/en unknown
- 2019-04-17 KR KR1020207032936A patent/KR102866133B1/ko active Active
- 2019-04-17 US US17/047,496 patent/US11993776B2/en active Active
- 2019-04-17 MX MX2020010959A patent/MX2020010959A/es unknown
- 2019-04-17 CA CA3097004A patent/CA3097004A1/en active Pending
- 2019-04-17 IL IL278019A patent/IL278019B1/en unknown
- 2019-04-17 WO PCT/US2019/027981 patent/WO2019204514A1/en not_active Ceased
- 2019-04-17 EP EP19789043.7A patent/EP3781213A4/en active Pending
- 2019-04-17 JP JP2020557945A patent/JP7561624B2/ja active Active
- 2019-04-17 CN CN201980040706.1A patent/CN112449605B/zh active Active
- 2019-04-17 BR BR112020021228-8A patent/BR112020021228A2/pt unknown
- 2019-04-17 AU AU2019255708A patent/AU2019255708B2/en active Active
-
2020
- 2020-10-15 MX MX2025007209A patent/MX2025007209A/es unknown
-
2024
- 2024-04-30 JP JP2024073380A patent/JP2024099770A/ja active Pending
- 2024-05-24 US US18/673,713 patent/US12442003B2/en active Active
-
2025
- 2025-09-17 US US19/331,448 patent/US20260078380A1/en active Pending
-
2026
- 2026-03-10 JP JP2026037564A patent/JP2026095408A/ja active Pending
- 2026-05-11 AU AU2026203595A patent/AU2026203595A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520837A5 (enExample) | ||
| JP2022551986A5 (enExample) | ||
| JP2024009857A5 (enExample) | ||
| JP6174318B2 (ja) | アデノ随伴ウイルス構築物を含んでなるコンダクティング気道細胞を標的とするための組成物 | |
| JP2022529631A5 (enExample) | ||
| JP2023534999A5 (enExample) | ||
| JP2022535749A5 (enExample) | ||
| JP2022524434A5 (enExample) | ||
| JP2022508182A5 (enExample) | ||
| JP2025515979A5 (enExample) | ||
| JP2021511803A5 (enExample) | ||
| JP2018522529A5 (enExample) | ||
| JP2020522269A5 (enExample) | ||
| JP2018516978A5 (enExample) | ||
| JP2021534814A5 (enExample) | ||
| JP2020500541A5 (enExample) | ||
| US20220380798A1 (en) | AAV Expression Cassette and AAV Vectors Comprising the Same | |
| JP6929230B2 (ja) | スペーサーを含む核酸分子およびその使用の方法 | |
| JP2022547197A5 (enExample) | ||
| JP2020054367A (ja) | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| JP2022525302A5 (enExample) | ||
| JP2022551744A5 (enExample) | ||
| JP2020512822A5 (enExample) | ||
| JP2023537358A5 (enExample) | ||
| JP2024530023A5 (enExample) |